Microbiotica Ltd., a spin out from the Wellcome Trust Sanger Institute, will use its metagenomics microbiome platform to analyse data from Genentech Inc.’s inflammatory bowel disease (IBD) trials to find biomarker signatures of drug response, novel IBD drug targets and live bacterial therapeutic products. This is Microbiotica’s first collaboration since its inception 18 months ago.
Genentech Mines The Microbiome Again With IBD Deal
Genentech is to work with microbiome therapeutics company Microbiotica in a collaboration to discover, develop and commercialise treatments for inflammatory bowel disease.
More from R&D
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from Scrip
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.